Table 3 Response to therapy for the 41 patients

From: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

 

Patients ( N =41)

Response

N

%

Overall response

22

54

 Complete response (CR)

5

12

 Partial response (PR)

17

42

Stable disease (SD)

6

14

Progressive disease (PD)

13

32

  1. Among these 41 patients, three were never treated with gefitinib, because they had to stop the first adminstration of i.v. docetaxel on day 1 of the first cycle before receiving gefitinib due to hypersensitivity reactions to docetaxel. Three additional patients refused further therapy after one cycle. Refusal was due to grade 3 diarrhoea in one patient and to grade 2 acne-like rash in the other two patients. For the intention to treat analysis, all six patients were recorded as patients with progressive disease.
Back to article page